bluuebunny/crossref_metadata_2025_split huggingface dataset:
Face masks versus sunglasses: limited effects of time and individual differences in the ability to judge facial identity and social traits
Authors: Bennetts Rachel J. , Johnson Humphrey Poppy , Zielinska Paulina , Bate Sarah 
Published: February 2022

AbstractSome research indicates that face masks impair identification and other judgements such as trustworthiness. However, it is unclear whether those effects have abated over time as individuals adjust to widespread use of masks, or whether performance is related to individual differences in face recognition ability. This study examined the effect of masks and sunglasses on face matching and social judgements (trustworthiness, competence, attractiveness). In Experiment 1, 135 participants across three different time points (June 2020–July 2021) viewed unedited faces and faces with masks, sunglasses, or both. Both masks and sunglasses similarly decreased matching performance. The effect of masks on social judgements varied depending on the judgement and whether the face was depicted with sunglasses. There was no effect of timepoint on any measure, suggesting that the effects of masks have not diminished. In Experiment 2, 12 individuals with developmental prosopagnosia (DP) and 10 super-recognisers (SRs) completed the same tasks. The effect of masks on identity matching was reduced in SRs, whereas the effects of masks and sunglasses for the DP group did not differ from controls. These findings indicate that face masks significantly affect face perception, depending on the availability of other facial information, and are not modified by exposure.
Patient radiation dose during angiography and embolization for abdominal hemorrhage: the influence of CT angiography, fluoroscopy system, patient and procedural variables
Authors: McCaughey Conor , Healy Gerard M. , Al Balushi Hanin , Maher Patrice , McCavana Jackie , Lucey Julie , Cantwell Colin P. 
Published: February 2022

Abstract
Background
Angiography and embolization (AE) is a lifesaving, high radiation dose procedure for treatment of abdominal arterial hemorrhage (AAH). Interventional radiologists have utilized pre-procedure CT angiography (CTA) and newer fluoroscopic systems in an attempt to reduce radiation dose and procedure time.

Purpose
To study the factors contributing to the radiation dose of AE for AAH and to compare to the reference standard.

Materials and methods
This retrospective single-centre observational cohort study identified 154 consecutive AE procedures in 138 patients (median age 65 years; interquartile range 54–77; 103 men) performed with a C-arm fluoroscopic system (Axiom Artis DTA or Axiom Artis Q (Siemens Healthineers)), between January 2010 and December 2017. Parameters analysed included: demographics, fluoroscopy system, bleeding location, body mass index (BMI), preprocedural CT, air kerma-area product (PKA), reference air kerma (Ka,r), fluoroscopy time (FT) and the number of digital subtraction angiography (DSA) runs. Factors affecting dose were assessed using Mann–Whitney U, Kruskal–Wallis one-way ANOVA and linear regression.

Results
Patients treated with the new angiographic system (NS) had a median PKA, median Ka,r, Q3 PKA and Q3 Ka,r that were 74% (p < 0.0005), 66%(p < 0.0005), 55% and 52% lower respectively than those treated with the old system (OS). This dose reduction was consistent for each bleeding location (upper GI, Lower GI and extraluminal). There was no difference in PKA (p = 0.452), Ka,r (p = 0.974) or FT (p = 0.179), between those who did (n = 137) or did not (n = 17) undergo pre-procedure CTA. Other factors significantly influencing radiation dose were: patient BMI and number of DSA runs. A multivariate model containing these variables accounts for 15.2% of the variance in Ka,r (p < 0.005) and 45.9% of the variance of PKA (p < 0.005).

Conclusion
Radiation dose for AE in AAH is significantly reduced by new fluoroscopic technology. Higher patient body mass index is an independent key parameter affecting patient dose. Radiation dose was not influenced by haemorrhage site or performance of pre-procedure CTA.
A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic
Authors: Noor Rashed 
Published: February 2022

Abstract
Background
To mitigate the current COVID-19 pandemic by the severe acute respiratory coronavirus 2 (SARS-CoV-2), designing of repurposed antiviral drugs and the development of vaccines using different platforms have been the most significant work by the scientists around the world since the beginning of 2020.

Main body of the abstract
While positive results are being noticed with the currently used vaccines, the emerging variants of SARS-CoV-2 as well as the second wave of COVID-19 pandemic put the global public health in the deadliest health issue. Present review attempted to focus on the development of the current COVID-19 situation in the light of knowledge gathered from the recently published literature. An important facet regarding the COVID-19 severity is the avoidance of host immunity by the SARS-CoV-2 and its variants. Indeed, the genetic similarities between SARS-CoV-2, SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) showed the viral escape strategies of the protective host immunity which appeared as the major problem for the effective vaccine development.

Short conclusion
Present review discussed the prescribed platforms of vaccine development and pondered on the cellular and humoral immune responses by vaccines; and apart from vaccination approaches, non-pharmaceutical intervention approaches have also been pondered based on modeling rules.
Bacterial communities in carnivorous pitcher plants colonize and persist in inquiline mosquitoes
Authors: Arellano Aldo A. , Coon Kerri L. 
Published: February 2022

AbstractBackgroundThe leaves of carnivorous pitcher plants harbor diverse communities of inquiline species, including bacteria and larvae of the pitcher plant mosquito (Wyeomyia smithii), which aid the plant by processing captured prey. Despite the growing appreciation for this microecosystem as a tractable model in which to study food web dynamics and the moniker ofW. smithiias a ‘keystone predator’, very little is known about microbiota acquisition and assembly inW. smithiimosquitoes or the impacts ofW. smithii-microbiota interactions on mosquito and/or plant fitness.ResultsIn this study, we used high throughput sequencing of bacterial 16S rRNA gene amplicons to characterize and compare microbiota diversity in field- and laboratory-derivedW. smithiilarvae. We then conducted controlled experiments in the laboratory to better understand the factors shaping microbiota acquisition and persistence across theW. smithiilife cycle. Methods were also developed to produce axenic (microbiota-free)W. smithiilarvae that can be selectively recolonized with one or more known bacterial species in order to study microbiota function. Our results support a dominant role for the pitcher environment in shaping microbiota diversity inW. smithiilarvae, while also indicating that pitcher-associated microbiota can persist in and be dispersed by adultW. smithiimosquitoes. We also demonstrate the successful generation of axenicW. smithiilarvae and report variable fitness outcomes in gnotobiotic larvae monocolonized by individual bacterial isolates derived from naturally occurring pitchers in the field.ConclusionsThis study provides the first information on microbiota acquisition and assembly inW. smithiimosquitoes. This study also provides the first evidence for successful microbiota manipulation in this species. Altogether, our results highlight the value of such methods for studying host-microbiota interactions and lay the foundation for future studies to understand howW. smithii-microbiota interactions shape the structure and stability of this important model ecosystem.
Risk stratification of endometrial cancer and lymph node metastases prediction using 18F-FDG PET/CT: role of metabolic tumor volume and total lesion glycolysis
Authors: Abdelkawi Mostafa M. , Sweed Mohamed S. , Ali Mohamed A. , NasrElDin Eman A. 
Published: February 2022

Abstract
Background
Endometrial cancer is the commonest gynecologic malignancy. Pelvic lymph node metastasis is considered one of its most important prognostic factors. Surgery is considered the most important and effective treatment, still there is controversy about indication and necessity of pelvic lymph node dissection. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is investigated in his study to evaluate its value in preoperative detection of lymph node metastases and risk stratification of endometrial cancer.

Results
Reviewing the records of 33 women with endometrial cancer, all 18F-FDG PET/CT studied indices, SUVmax, SUVmean, MTV and TLG, mean difference was statistically significant in all the studied risk categories (tumor grade, Myometrial invasion, lymphovascular space invasion, tumor stage, and risk stratification). SUVmax and TLG showed highest area under the curve for detection of Myometrial invasion > 50% (AUC = 0.911) with cut-off value of SUVmax > 14.55 showing 88.89% sensitivity and 86.67% specificity, and TLG > 192.653 having 88.89% sensitivity and 80% specificity. TLG showed highest AUC (0.889 and 0.921) for detection of LVSI and LNMs with 100% sensitivity and 66.67% specificity for cut-off value > 179.374 and 88.89% sensitivity and 83.33% specificity for cut-off value > 249.366, respectively. Concerning risk stratification of EC, SUVmax and TLG showed highest AUC (0.839) with cut-off value > 14.55 showing 77.27% sensitivity and 90.91% specificity, and > 192.653 having 77.27% sensitivity and 81.82% specificity, respectively.

Conclusion
The results of this study suggest that 18F-FDG PET/CT is a very valuable tool for prediction of lymph node metastases and risk stratification in endometrial cancer patients. Applying TLG cutoff values increases the accuracy and preoperative diagnosis of lymph node metastases which aids in sparing women with low-risk early stage EC unnecessary surgical risk and morbidity of lymphadenectomy.
A rule-based model for electricity theft prevention in advanced metering infrastructure
Authors: Otuoze Abdulrahaman Okino , Mustafa Mohd Wazir , Abioye Abiodun Emmanuel , Sultana Umbrin , Usman Ayinde Muhammed , Ibrahim Oladimeji , Omeiza Isaac Ozovehe Avazi , Abu-Saeed Abdallah 
Published: February 2022

AbstractThe deployment of smart electricity meter (SEM) via the advanced metering infrastructure (AMI) has come under cyber-attacks as adversaries continue to exploit the communication links for possible evasion of electricity bill payments. Various detection models relying on energy consumption data offer a disadvantage of delayed detection and consequent huge financial losses before frauds are detected. Moreover, existing techniques mostly concentrate on detection of electricity thefts and rely on energy consumption data alone as the basis of theft perpetration whereas other potential parameters which could be exploited for electricity theft prevention exist in AMI. In this study, AMI parameters, which are indicative of electricity thefts are preselected and modelled for electricity theft prevention. First, a given AMI network is sectioned into zones with the selected parameters modelled to define security risks by formulated set of rules based on real-time scenarios. Fuzzy inference system is then employed to model the security risks to ascertain the compromised state of the monitored parameters at the defined scenarios. The result of the developed model at 50% weight of each of the modelled parameters with interdependencies show clear indications of the modelled parameters and their interactions in the determination of risks. The decisions on monitored parameters evaluated at every timestep reveal varied dense velocity behaviours for every scenario. The result is suitable for monitoring the AMI in reporting and/or disconnecting any compromised SEM within a considerable timestep before huge losses are incurred. Implementation of this scheme will contribute a significant success in the attempt to prevent electricity theft perpetration via the AMI.
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Authors: Berruti Alfredo , Fassnacht Martin , Libè Rossella , Lacroix Andrè , Kastelan Darko , Haak Harm , Arlt Weibke , Decoudier Bénédict , Lasolle Hélène , Bancos Irina , Quinkler Markus , Barisson Villares Fragoso Maria Candida , Canu Letizia , Puglisi Soraya , Bourdeau Isabelle , Baudin Eric , Berchialla Paola , Beuschlein Felix , Bertherat Jerome , Terzolo Massimo 
Published: February 2022

1 Background: The ESE-ENSAT guidelines on ACC management suggest adjuvant mitotane for patients at high risk of recurrence. This indication has limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane or observation. The primary endpoint of the study was RFS. Patients who refused randomization were eligible for the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in ADIUVO except for randomization. A total of 91 patients were enrolled in ADIUVO, 45 in the mitotane and 46 in the observation arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with mitotane and observation groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohort was analyzed in parallel to deal with the lower than expected recruitment in ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55-3.32, p = 0.54) and HR for death 2.171 (95%CI, 0.52-12.12, p = 0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed that of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-yr RFS is 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care. Clinical trial information: NCT00777244.
Statin use and survival in men receiving androgen-ablative therapies for advanced prostate cancer: A systematic review and meta-analysis of cohort studies.
Authors: Jayalath Viranda Helitha , Clark Roderick , Lajkosz Katherine , Fleshner Neil E. , Hamilton Robert James 
Published: February 2022

83 Background: Mounting evidence support a role for statins in improving survival in advanced prostate cancer (PC), particularly among men on androgen-ablative therapies. This study aimed to systemically review and meta-analyze the relationship between statin use and survival among men with PC on androgen deprivation therapy (ADT) or androgen receptor-axis-targeted therapies (ARATs). Methods: This review was conducted in accordance with the Cochrane Handbook for Systematic Reviews and reported in compliance with the MOOSE guidelines. Medline, Embase, Epub Ahead of Print, Cochrane CT, Cochrane SR, and Web of Science were searched from inception to May 18, 2021, for observational studies reporting associations of postdiagnostic statin use and survival outcomes (hazard ratios [HRs]). Two authors independently abstracted all data. Study quality was assessed using the Newcastle-Ottawa Scale. The primary outcomes included overall mortality (OM) and Prostate cancer-specific mortality (PCSM). Summary estimates pooled multivariable HRs with 95% confidence intervals (CIs) using the generic inverse variance method with random-effects modelling. Heterogeneity was assessed and quantified. A priori subgroup and sensitivity analyses were undertaken, and publication bias was evaluated. Confidence in the evidence was assessed using GRADE. Results: Twenty-five cohorts of 119,878 men (64,717 statin users [54%]) with over 74,416 mortality events were included. Postdiagnostic statin use was associated with a 27% reduction in the risk of OM (19 cohorts, HR 0.73 [95%CI: 0.66 to 0.82], I2= 83%) and a 35% reduction in the risk of PCSM (14 cohorts, HR 0.65 [95%CI: 0.58 to 0.73], I2= 74%), with significant heterogeneity in both estimates. Subgroup analyses identified a PCSM-advantage of statins for men on ARATs compared to ADT (HR 0.40 [95%CI: 0.30 to 0.55] vs HR 0.68 [95%CI: 0.60 to 0.76], p-difference < 0.01). Confidence in the overall evidence was “low” for both outcomes. Conclusions: Postdiagnostic statin use reduced both overall and prostate cancer-specific mortality in men on androgen-ablative therapies for advanced PC. Randomized controlled trials are warranted to validate these findings.
Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.
Authors: Yip Steven , Niazi Tamim , Hotte Sebastien J. , Lavallee Luke , Finelli Antonio , Kapoor Anil , Kolinsky Michael Paul , Ong Michael , Pouliot Frederic , Antebi Elie , Drachenberg Darrel , Gotto Geoffrey , Hamilton Robert James , Noonan Krista , Rendon Ricardo A. , Shayegan Bobby , Zardan Anousheh , Chi Kim N. , Saad Fred , Morash Chris 
Published: February 2022

86 Background: Treatment options for patients with mCSPC have rapidly evolved with the introduction of androgen receptor axis targeted therapies (ARATs) and chemotherapy. The GURC cohort study is a phase 4, multicentre, non-interventional, longitudinal cohort study of Canadian men with advanced prostate cancer. We prospectively examined the evolving real world management and treatment patterns of patients with mCSPC, with a focus on treatment intensification beyond ADT and germline DNA damage repair (DDR) testing. Methods: Clinical management patterns, baseline patient characteristics, germline DDR alteration status, treatment intensification with ARATs (abiraterone acetate [AA], apalutamide [Apa], enzalutamide [Enza]) and chemotherapy within the mCSPC cohort were analyzed. Results: 204 patients with mCSPC were enrolled from 2018 to 2021 across 25 Canadian sites. The median age was 71 (range 64 - 77), median PSA at study entry was 24, 88% (158/180) of patients had de novo mCSPC, 69% (110/204) of patients had a Gleason Score > 7, and 4% (2/49) of the patients who received a germline testing harbored a germline DDR alteration (BRCA2 = 1, MUTYH/MEN1 = 1). The distribution of high and low volume mCSPC at study entry was 62% (118/189) and 37% (71/189), respectively. Overall, patients received ADT alone 27% (51/189), AA 45% (86/189), apalutamide 17% (33/189), docetaxel 8% (15/189), and enzalutamide 3% (6/189). Treatment intensification with ARATs/docetaxel was administered to 69% [141/189]) of patients. Patients treated with ADT alone had a significantly lower volume of disease at treatment initiation (low volume rates of 49% [24/49] in ADT alone vs 33% [47/143] in treatment intensified patients, p = 0.044). Among those receiving treatment intensification with ARATs/docetaxel, time to intensification was ≤ 3 months in 78.5 % (113/144). Conclusions: This cohort study demonstrates that patients with mCSPC continue to receive ADT alone and docetaxel over time, despite an ever-increasing list of accessible ARATs. Patients receiving ADT alone appear to have lower volume of disease. Germline DDR testing is not yet comprehensively performed. This underlines the real world need to provide greater education and resources to encourage ARAT treatment and genetic testing in this setting.
Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis.
Authors: Naqvi Syed Arsalan Ahmed , Bin Zafar Muhammad Daim , Islam Mahnoor , Ikram Waleed , Raina Ammad , Singh Parminder , Riaz Irbaz Bin , Bryce Alan Haruo 
Published: February 2022

134 Background: Recent trials have suggested poly ADP-ribose polymerase inhibitors (PARPi) sensitivity in patients with treatment-refractory metastatic castration-resistant prostate cancer (mCRPC) harboring mutations in DNA damage and response repair genes (DDR). However, the efficacy profile might differ with different genes and is still being explored in multiple studies. Methods: We systematically searched several electronic databases (MEDLINE, EMBASE), and conference proceedings to include abstracts and full-text publications of phase II/III trials evaluating PARPi in treatment-refractory mCRPC with DDR gene alterations. Outcomes of interest included objective response rate (ORR), complete response (CR), prostate specific antigen (PSA) 50% response, circulating tumor cells conversion (CTCc) from ≥ 5 to < 5 cells, composite response (CoR) and risk of progression. Data was pooled using Inverse-variance approach. A DerSimonian and Laird random-effect meta-analysis was conducted to estimate pooled proportion (PP) of events using the Freeman-Tukey transformation in each gene. Clopper-Pearson method was used to estimate the associated 95% confidence intervals (CI). Results: This systematic review and meta-analysis included five unique trials with 648 patients and four PARPi (niraparib, olaparib, rucaparib, talazoparib). Objective response to PARPi was observed in 44.7% of patients with mutations in either BRCA1 or 2 or both (95% CI: 36.0%-53.6%; I2: 0%), 23.5% with ATM (95% CI: 3.91%-51.0%; I2: 65%), 25.0% with CDK12 (95% CI: 8.66%-49.1%), and 45.3% with PALB2 alterations (95% CI: 14.8%-77.5%; I2: 0%). Consistent results were observed for CR outcome. PSA50% response to PARPi was observed in 60.3% of patients with BRCA1/2 mutations (95% CI: 50.3%-70.0%; I2: 57%), 5.54% (95% CI: 0.01-16.6; I2: 0%) with ATM, and 70.1% (95% CI: 35.6%-96.6%; I2: 0%) with PALB2 mutations while no PSA 50% response was observed in patients with CDK12 mutations (PP: 0.00%; 95% CI: 0%-16.84%). Moreover, CTCc was observed in 68.3% of patients with BRCA1/2 mutations (95% CI: 45.0%-87.8%; I2: 77), 34.2% (95% CI: 11.2-61.3%; I2: 45%) with ATM, 41.7% (95% CI: 15.2%-72.3%) with CDK12, and 48.5% (95% CI: 6.39%-92.9%; I2: 49%) with PALB2. CoR was observed in 76.5% patients with BRCA1/2 mutations (95% CI: 65.4%-86.1%; I2: 22%), 30.4% (95% CI: 16.0%-46.9%) with ATM, 25% (95% CI: 8.66%-49.1%) with CDK12, and 63.9% (95% CI: 31.0%-91.8%; I2: 0%) with PALB2 mutations. Similarly, the risk of progression was 50.9% in patients with BRCA1/2 mutations (95% CI: 37.7%-63.9%), 70.9% (95% CI: 60.0%-80.40%; I2: 0%) with ATM, and 75% (95% CI: 19.4-99.3%) with PALB2. Conclusions: Current evidence is sparse regarding efficacy by specific genes. Limited data favors the use of PARPi in mCRPC patients harboring mutations in BRCA1/2 and PALB2 genes.